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Abstract
Introduction Congenital nephrotic syndrome (CNS) is an ultra-rare disease associated with a pro-thrombotic state and venous
thromboembolisms (VTE). There is very limited evidence evaluating thromboprophylaxis in patients with CNS. This study
aimed to determine the doses and duration of treatment required to achieve adequate thromboprophylaxis in patients with CNS.
Methods From 2005 to 2018 children in Scotland with a confirmed genetic or histological diagnosis of CNS were included if
commenced on thromboprophylaxis. The primary study endpoint was stable drug monitoring. Secondary outcomes included
VTE or significant haemorrhage.
Results Eight patients were included; all initially were commenced on low-molecular weight heparin (enoxaparin). Four patients
maintained therapeutic anti-Factor Xa levels (time 3–26 weeks, dose 3.2–5.07 mg/kg/day), and one patient developed a throm-
bosis (Anti-Factor Xa: 0.27 IU/ml). Four patients were subsequently treated with warfarin. Two patients maintained therapeutic
INRs (time 6–11 weeks, dose 0.22–0.25 mg/kg/day), and one patient had two bleeding events (Bleed 1: INR 6, Bleed 2: INR
5.5).
Conclusions Achieving thromboprophylaxis in CNS is challenging. Similar numbers of patients achieved stable anticoagulation
on warfarin and enoxaparin. Enoxaparin dosing was nearly double the recommended starting doses for secondary
thromboprophylaxis. Bleeding events were all associated with supra-therapeutic anticoagulation.
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Abbreviations
BNFc British National Formulary for Children
CNS Congenital Nephrotic Syndrome
CVVH Continuous veno-venous hemofiltration
eGFR Estimated glomerular filtration rate
INR International Normalised Ratio
LMWH Low molecular weight heparin
SVC Superior vena cava
VTE Venous Thromboembolism
UPCR Urinary protein:creatinine ratio
Introduction
Congenital nephrotic syndrome (CNS) is a rare disease
characterised by heavy proteinuria and severe oedema devel-
oping within 3 months of birth [1, 2]. Glomerular filtration
barrier proteins are defective due to genetic mutations or more
rarely secondary to congenital viral infection. Complications
arising from severe proteinuria include venous thromboembo-
lism (VTE), recurrent infection, fluid and electrolyte distur-
bance, and impaired growth [3]. The increased VTE risk is
predominantly attributed to urinary loss of proteins important
in coagulation regulation, exacerbated by the common re-
quirement in this patient group for long-term central venous
access [4–6]. Loss of haemostatic proteins, e.g., antithrombin
III, leads to an up-regulation in hepatic coagulation factor
synthesis and thus a pro-thrombotic tendency [7–10].
Several studies report a VTE prevalence of 10–29% of CNS
patients over their disease course; this variability being partly
attributed to the marked genotypic and phenotypic variation in
CNS [1, 11, 12].
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To mitigate the thrombotic risk, management includes
strategies to reduce urinary protein loss and administration
of anticoagulant therapies. Protein loss is minimised by bilat-
eral nephrectomy and early use of dialysis, or unilateral ne-
phrectomy in combination with angiotensin converting en-
zyme inhibitors and prostaglandin inhibitors to decrease
GFR [4, 13]. Anticoagulation agents commonly used are war-
farin and enoxaparin. Warfarin, a vitamin K antagonist, is
monitored using the international normalised ratio (INR).
The target INR is between 2.0 and 3.0 for primary
thromboprophylaxis [14]. Enoxaparin, a low molecular
weight heparin (LMWH), binds to anti-thrombin leading to
inhibition of activated factor X. Anti-factor Xa assays are used
tomonitor efficacy, with a target level between 0.2 and 0.4 IU/
ml for primary thromboprophylaxis [14, 15]. If a thrombotic
event has already occurred, levels are targeted at 0.5–1 IU/ml
for secondary thromboprophylaxis. Aspirin is less frequently
used as thromboprophylaxis in CNS and is not utilised within
our unit. Unfractionated heparin is not suitable as it requires
continuous infusion, as well as an extensive adverse effect
profile [2]. Direct oral anticoagulants have not been studied
in CNS.
Thromboprophylaxis in children is challenging due to rap-
id growth velocity and physiological changes in pharmacoki-
netics, especially in the early years of life [16, 17]. Fung et al.
demonstrated that therapeutic anti-factor Xa levels required an
average of 1.64 mg/kg and 1.45 mg/kg of enoxaparin for
children under 1 year and aged 1 to 6 years, respectively
[16, 18]. Thromboprophylaxis using LMWH in CNS is fur-
ther complicated by antithrombin III deficiency (due to uri-
nary loss) causing heparin resistance [19]. Warfarin also has
challenges in infancy, as metabolism is influenced by comor-
bidities, medications, and dietary changes. Similar to
enoxaparin, higher doses are typically required in infants than
children with doses of ~ 0.32 mg/kg and ~ 0.09 mg/kg report-
ed in children under 1 and over 11, respectively [20]. Infants
also typically require longer treatments to achieve target INRs
and more frequent dose adjustments when compared with
older children [21].
The extreme rarity of CNS is a significant limitation on the
ability to undertake a clinical trial of thromboprophylaxis.
Therapeutic decisions are based on patient preference and cli-
nician experience. In a recent European multi-centre retro-
spective review of anticoagulation in CNS, 5/45 (11%) pa-
tients receiving anticoagulant therapy and 4/26 (15%) not re-
ceiving anticoagulants developed VTE (p = 0.60) [22].
Anticoagulant therapies in patients experiencing VTE were
warfarin (n = 3), heparin (n = 1), and aspirin (n = 1). Despite
participation by 17 tertiary centres, the rarity of CNS and VTE
as an outcome precluded formal statistical analysis due to
small numbers. Additionally, therapeutic monitoring was not
reported, making it uncertain whether VTE occurred due to
inadequate thromboprophylaxis in the ‘anticoagulated’
cohort. Our own observation was that patients often required
high doses of anticoagulant agents to achieve sufficient ther-
apeutic levels. This case series aims to report whether signif-
icantly higher doses of anticoagulants are required to achieve
adequate thromboprophylaxis in patients with CNS. We
hypothesised that patients will require high doses of anticoag-
ulants with a prolonged time taken to reach therapeutic levels.
Methods
Data were obtained from patients admitted to the Royal
Hospital for Children, Glasgow. Patients were included if
CNS was diagnosed from 1 July 2005 until 1 January 2018.
The database was locked on 1 June 2020. As a single national
paediatric nephrology centre, this represents all CNS cases in
Scotland in that time period. The data were collected retro-
spectively using clinical portal (TrakCare, InterSystems cor-
poration) and the Strathclyde electronic renal patient record
(SERPR) (VitalDataClient, v1.6.0.9493). Graphs were pro-
duced using GraphPad Prism version 8 (GraphPad Software,
San Diego, CA).
Data collected included basic demographic data, length,
weight, serum creatinine, serum albumin, urinary
protein:creatinine ratio, factor Xa assays, INR, antithrombin
III levels, thromboprophylaxis dose in mg/kg/day, concomi-
tant medications, albumin infusion data, genetic analyses
(where performed), any confirmed thrombo-embolic events,
and any confirmed haemorrhagic events (both determined by
clinical discussion).
Estimated glomerular filtration rate (eGFR) was calculated
using the Bedside IDMS-traceable Schwartz GFR equation
(GFR (ml/min/1.73 m2) = (36.2 × length (cm))/creatinine
(μmol/l)). In cases where length data was unavailable early
in clinical course (n = 3), growth chart values were extrapo-
lated backwards along their centile to provide an estimate of
length at the time of presentation.
The primary study endpoint was effective and stable
thromboprophylaxis, defined as three consecutive therapeutic
measurements. Therapeutic levels of enoxaparin were defined
as anti-factor Xa levels of 0.2–0.4 IU/ml; therapeutic
warfarinisation was defined as INR between 2.0 and 3.0. In
patients where a thrombotic event occurred prior to
anticoagulation, secondary thromboprophylaxis levels were
targeted to anti-factor Xa levels of 0.5–1.0 IU/ml. Secondary
endpoints were bilateral nephrectomies, transplantation, or the
development of stage 5 chronic kidney disease (CKD 5), de-
fined as confirmed eGFR < 15 ml/min/1.73 m2 (i.e., the value
was calculated using a measured height, not via extrapola-
tion). Where patients switched thromboprophylaxis modality,
data were also collected from the onset of the second therapy,
until the same endpoint was reached. Secondary outcomes
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included clinically confirmed VTE or any clinically signifi-
cant episode of haemorrhage.
Results
Eleven children had a confirmed diagnosis of CNS between 1
July 2005 and 1 January 2018. Three children were not in-
cluded. One child died at 2 weeks of age, one presented ini-
t ia l ly with severe acute kidney injury requir ing
haemofiltration and had a persistent requirement for dialysis
thereafter for fluid removal (patient 9), and the third was in
CKD 5 at the time of presentation (patient 10). Table 1 sum-
marises the relevant demographic, phenotypic, and clinical
details of all included patients. Supplementary Table 1 sum-
marises excluded patients. There were five male patients and
three female, with clinical presentation at a mean age of 6
weeks (range 2–15 weeks). Clinically, one patient had
Pierson syndrome and two had Denys Drash syndrome.
Histologically, four patients had diffuse mesangial sclerosis,
two patients had ‘stage 5’ histological findings, one patient
had mild glomerular change only, and one patient had no
biopsy undertaken. Mutational analysis showed that five pa-
tients had mutations affecting NPHS1, one had a LAMB2mu-
tation, and two had WT1 mutations. Table 2 details the muta-
tional analyses in patients where available. The eGFR at pre-
sentation was highly variable between patients (range 16–177
ml/min/1.73 m2) as was presenting serum albumin (range 6–
21 g/L). Proteinuria data was available for 5/8 patients at pre-
sentation (range 3.81–9.63 g/mmol). Antithrombin III levels
were measured in 2 patients at presentation, both below the
normal range (patients: 25–61 IU/dL, normal: 71–101 IU/dL).
Measurement of antithrombin III is not routine in our institu-
tion, and no other results at presentation were available.
All patients had a central venous catheter (CVC) inserted
for either the delivery of intravenous albumin or the provision
of haemodialysis. The albumin requirement varied from 6.3 to
31.5 g/kg/week. Further detail on albumin requirements are
provided in Supplementary Table 2. Standard medical man-
agement in our unit also included regular administration of
phenoxymethylpenicillin (penicillin V), levothyroxine as
needed, angiotensin-converting enzyme inhibition (ACEi),
and anti-reflux medications.
Enoxaparin dosing
All included patients were commenced on LMWH
(enoxaparin) as a first-line thromboprophylaxis agent, at a
mean starting dose of 1.88 mg/kg/day (range 0.71–4.3
mg/kg/day). The dose then subsequently varied from 0.71
mg/kg/day to a maximum of 7.44 mg/kg/day. All patients
received subcutaneous administration twice a day with anti-
factor Xa levels measured at 4 to 6 h post-dose. No patients
received enoxaparin via infusion. Antithrombin III levels were
not routinely measured, though 3 patients had at least one
measurement (always below normal). No patient received an-
tithrombin III infusions.
Figure 1 details graphs of enoxaparin dosing, anti-factor Xa
levels, eGFR, and serum albumin (Supplementary Figure 1
replaces serum albumin with urinary protein:creatinine ratio
where available). Four patients reached therapeutic anti-factor
Xa levels with the dose varying from 3.2 to 5.07 mg/kg/day.
and time taken varying from 3 to 28 weeks (Table 1; patient 2
and 3: 6 weeks, 4.0 mg/kg/day and 5.07 mg/kg/day, respec-
tively; patient 5: 26 weeks, 4.79 mg/kg/day; patient 8: 3
weeks, 1.82 mg/kg/day). Four patients did not reach therapeu-
tic anti-factor Xa levels. Two patients reached CKD 5 before
therapeutic levels were achieved, resulting in discontinuation
of anticoagulation. Two patients had discontinuation due to
failure to achieve adequate levels despite dose escalation, oc-
curring after 25–27 weeks of therapy. The patients achieving
therapeutic LMWH levels had NPHS1 compound heterozy-
gote or WT1 mutations (patients 2, 3, and 5 = NPHS1 com-
pound heterozygote, patient 8 = WT1 mutation). An apparent
inverse relationship was noted between eGFR and anti-factor
Xa levels, i.e., a decrease in eGFR associated with an increase
in anti-factor Xa levels as might be physiologically expected.
Serum albumin was proportional, with a higher serum albu-
min associated with higher anti-factor Xa levels.
Warfarin dosing
Four patients were subsequently commenced on warfarin, at a
mean starting dose of 0.19 mg/kg/day (range 0.18–0.2 mg/kg/
day). The dose then varied from 0.18 mg/kg/day to a maxi-
mum of 0.89 mg/kg/day.
Figure 2 details graphs of warfarin dosing, INR, eGFR and
serum albumin (Supplementary Figure 2 replaces serum
albumin with uPCR for patient 5). Two patients reached ther-
apeutic INRs with doses from 0.22 to 0.25 mg/kg/day and
time taken varying from 6 to 11 weeks (Table 1; patient 1:
11 weeks, 0.22 mg/kg/day; patient 2: 6 weeks, 0.25 mg/kg/
day). Two patients did not reach therapeutic INR. Patient 4 did
not reach therapeutic levels after 1 year and patient 5 was
discontinued from warfarin after 22 weeks due to concerns
regarding bleeding. For eGFR and INR the graphs again show
an inverse relationship.
Supplementary figure 3 provides similar information for
non-included patients 9 and 10.
Adverse events
Tables 3 and 4 summarise identified adverse events in includ-
ed patients (clinical vignette 1 provides the same for patient 9).
Relevant kidney parameters and anticoagulation data at the
time are included. Supplementary Table 3 details concomitant
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medications at the time of adverse events. There were two
bleeding events and one thrombotic event during follow-up.
One thrombotic event occurred prior to thromboprophylaxis
in this cohort.
Bleeding
Patient 5 had two bleeding events after 5 and 11 weeks of
therapy, both whilst on warfarin. This coincided with a
supratherapeutic INR. The patient was haemodynamically sta-
ble on both occasions. The first bleeding event occurred 3
months following unilateral nephrectomy, whilst on home
IV albumin. The patient presented with fresh red blood evi-
dent in the stool, with visible clot. The patient’s gastrostomy
was noted to be leaking with evidence of superficial infection.
Indomethacin was temporarily discontinued, IV omeprazole
administered, and warfarin withheld. The INR was 6. Packed
red cells were transfused to improve haemoglobin (pre-
transfusion, 54 g/L). Twelve hours post-presentation, there
was fresh blood leakage from the gastrostomy, coinciding
with coffee-ground vomiting. IV vitamin K was administered
at a dose of 30 mg/kg to reverse over-warfarinisation without
preventing ongoing thromboprophylaxis. Warfarin was with-
held for 48 h then re-commenced at the original dose.
The second bleeding event occurred 1 week following an
upper respiratory tract infection, 1 month after the initial
bleeding event, presenting again with blood-specked vomitus
and fresh blood leakage from the gastrostomy. Haemoglobin
had fallen from 99 to 70 g/L. INR was ‘unrecordable’ twice,
so IV vitamin K was administered, again at 30 mg/kg. Repeat
INR 6 h later was 5.5. Transfusion was not required on this
occasion. Warfarin was recommenced at a slightly lower dose
after 72 h.
Two months later, the same patient then had an incidental
finding of an INR of 8.8 with no associated bleeding symp-
toms. At that point, warfarin was discontinued and the patient
re-commenced on LMWH.
Thrombus
No thrombotic complications developed whilst patients were
adequately warfarinised.
Patient 6 had identification of a femoral vein thrombus
aged 4 months, 2 weeks following initial presentation. Initial
managemen t r equ i r ed con t inuous veno-venous
haemofiltration (CVVH) initially via a femoral CVC, which
was changed to a left internal jugular CVC 3 days into thera-
py. CVVH was discontinued after 4 days, and the patient was
commenced on enoxaparin. One week later, the patient devel-
oped evident discrepancy in leg size, with identification of
non-occlusive thrombus within the right femoral vein. This
coincided with a thromboprophylactic anti-factor Xa level of
0.27 IU/ml. At the time of thrombus detection, the patient was
proteinuric (uPCR of 41.72 g/mmol), hypoalbuminaemic (13
g/L), and had a mild thrombocytosis (454 × 109/L). Following
detection of the thrombus, the target anti-factor Xa was tem-
porarily increased to 0.5–1.0 IU/ml until the clot resolved, and
for 3 months subsequently.
Patient 8 developed a superior vena cava (SVC) thrombus
5 days following initial insertion of an internal jugular CVC at
2 weeks of age, pr ior to the commencement of
anticoagulation. Enoxaparin was subsequently initiated as
secondary thromboprophylaxis, with target levels of 0.5–1.0
IU/ml. Of note, the patients’mother also had Grave’s disease,
which may have further exacerbated thrombosis risk.
At the time of database lock, two patients had successfully
been transplanted, four patients had died (cause of mortality:
sepsis = 1, cardiomyopathy = 1, intestinal obstruction and
perforation = 1, probable autonomic failure = 1), one patient
was on peritoneal dialysis, and one had ongoing CKD stage 3.
Table 2 Complete mutational analyses for all patients
Patient Genetics
1 NPHS1: Homozygous mutation
c.2417c > G
Highly likely to be pathogenic
2 NPHS1: Compound heterozygote
c.523C > T exon 5, nonsense
c.1379G > A exon 11, missense
Both highly likely pathogenic
3 NPHS1: Compound heterozygote
c.1954C > T exon 15, nonsense
c.2335-1G > A intron 17, skip/frameshift
Likely pathogenic and highly likely pathogenic respectively
4 NPHS1: Compound heterozygote
c.2335-1G > A intron 17 – skip/frameshift
c.2491C>T exon 18 missense
Highly likely pathogenic and likely pathogenic respectively
5 NPHS1: Compound heterozygote
c.2227C > T exon 17 – missense
c.2335-1G > A intron 17 – skip/frameshift
Both classed highly likely pathogenic
6 WT1: Heterozygous
c.[443-6C>A];[=]
Classed as unlikely pathogenic
7 LAMB2: Homozygous splice site variant in intron 25
c.3982 + 1G > T
Pathogenic, unknown effect but predicted to skip exon 25




c.736C > T exon 7 – missense
Pathogenic
10 WT1: Heterozygous
c.1181G > A exon 9 – missense
NPHS1 nephrin, LAMB2 beta-2-laminin, WT1 Wilms tumour 1
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Discussion
This case series describes the challenges in achieving effective
and safe thromboprophylaxis in patients with CNS.
Enoxaparin led to adequate thromboprophylaxis in 4/8 pa-
tients compared with 2/4 patients on warfarin, with variable
therapeutic times and doses. Both agents had similar safety
profiles. All bleeding complications were associated with
supra-therapeutic measurements, highlighting the requirement
for careful monitoring. Anti-factor Xa levels and INR appear
to have an inverse relationship with kidney function, as might
be physiologically expected. Loss of kidney function reduces
proteinuric losses of antithrombin III and other relevant pro-
teins, which may contribute to more effective anticoagulation.
The British National Formulary for children (BNFc) is the
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Fig. 1 Enoxaparin data. Graphs
demonstrating individual patient
enoxaparin dosing, therapeutic
monitoring using anti-factor Xa,
eGFR, and serum albumin. The
left y-axis displays eGFR and se-
rum albumin data; the right y-axis
displays enoxaparin dose and
anti-factor Xa level. The grey
shaded area represents the target
therapeutic range for
thromboprophylaxis. The vertical
grey dotted line represents an ad-
verse event
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enoxapar in dose of 1 mg/kg/day for secondary
thromboprophylaxis for children aged over 2 months (an ini-
tial dose of 2 mg/kg/day is recommended under 2 months, due
to differences in infant drug handling) [23]. International
guidelines suggest higher doses for younger children [14].
Our study cohort all received higher doses than BNFc guide-
lines, both initially and once therapeutic. Themean initial dose
in our cohort was 1.88 mg/kg/day, nearly double the recom-
mended starting dose, with the therapeutic dose ranging from
3.2 to 5.07 mg/kg/day. The mean enoxaparin dose required to
achieve adequate primary thromboprophylaxis was 4.27
mg/kg/day, over 4 times the suggested dose. The requirement
for higher doses may be attributable to a generally younger
age, lower antithrombin III levels related to proteinuric loss
(below the normal range in all patients where measurement
was performed; Table 1), and potentially other relevant uri-
nary losses [14, 18]. Dosing variability likely also reflects the
genotypic and phenotypic differences within our small cohort,
including the degree of proteinuria. Though therapeutic mon-
itoring is not generally undertaken in adults on enoxaparin, the
volatile nature of both proteinuria and kidney function man-
dates monitoring in paediatric patients. All patients in this
cohort had administration of enoxaparin twice daily, though
once daily dosing is also described. Though there are no re-
ported differences in safety or efficacy between a once or
twice daily dosing regimen, the available pharmacokinetic
data supports a twice daily dosing regimen [24, 25].
As expected, warfarin dosing was variable between pa-
tients and required careful titration and monitoring, similar
to other patient groups. Our cohort’s mean initial dose was
0.19 mg/kg, similar to the recommended initial dose of 0.2
mg/kg. Our cohort reflects the known literature, with warfarin
dosing ranging from 0.18 to 0.89 mg/kg, and a mean dose of
0.24 mg/kg achieving an INR suitable for primary
thromboprophylaxis. In one prospective study, infants re-
quired higher doses of warfarin than older children, with in-
fants under 1 requiring ~ 0.32 mg/kg, whereas children over
11 years required ~ 0.09 mg/kg [20]. Patient 4 never reached a
therapeutic INR despite dose escalation to 0.89 mg/kg.
Warfarinisation of children is challenging, even more so in
patients with ongoing alterations in their haematologic phys-
iology [16, 21].
To our knowledge this is the first study to address and
report actual monitoring of thromboprophylaxis in a national
cohort of CNS patients. A recent multi-centre retrospective
review of anti-thrombotic prophylaxis was carried out in 17
centres over 15 European countries. The investigators report-
ed that 4/45 (11%) receiving anticoagulants and 5/26 (15%)
not receiving anticoagulants developed VTEs (p = 0.60).
Notably, the majority of VTEs in that cohort occurred whilst
patients were warfarinised (warfarin in 3, heparin in 1, aspirin
in 1). This finding contrasts with our observation of VTEs
only occurring in a heparinised patient, though our cohort is
both smaller and has a different genetic mix (69%NPHS1 and
14% WT1 in Dufek et al., 50% and 25% respectively for our
cohort) [22]. A separate retrospective review of anticoagulated
CNS patients reported a VTE rate of 29% (16/55). About 67%
(37/55) of that cohort had anNPHS1mutation, and no patients
had a LAMB2 mutation—unlike the 2/8 in our cohort [11].
Our cohort has a relatively high prevalence of non-NPHS1
mutations or novel NPHS1 mutations, which may limit the
comparability and generalisation of our results. Neither of
the two larger studies reported assays indicating effective
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Fig. 2 Warfarin data. Graphs demonstrating individual patient warfarin
dosing, therapeutic monitoring using INR, eGFR, and serum albumin.
The left y-axis displays eGFR and serum albumin data; the right y-axis
displays warfarin dose and INR. The grey shaded area represents the
target therapeutic range for thromboprophylaxis. The vertical grey
dotted line represents an adverse event
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Two further retrospective studies have investigated prophy-
lactic anticoagulation in adults with nephrotic syndrome (NS).
A Danish retrospective analysis investigated 79 patients; of
whom 44 were anticoagulated and 35 were not and reported a
significant reduction in thrombotic events (4 versus 0 episodes,
p = 0.035) in patients receiving anticoagulant therapy without
increasing bleeding episodes (p = 0.45) [26]. A second retro-
spective study reported thrombotic events in 1.39% (2/143) of
anticoagulated patients and concluded that anticoagulation ef-
fectively reduced the VTE rate in nephrotic syndrome which
reportedly ranges from 7 to 40% [27]. Though the adult NS
literature suggests a role for thromboprophylaxis in reducing
the VTE risk, the aetiology of adult NS is very different, even
to idiopathic childhood NS, which is a further separate clinico-
pathological entity to CNS, including the degree of proteinuria
which is typically many fold higher in CNS than idiopathic NS.
Extrapolating findings from adult studies to this patient cohort
must be done with caution.
Within our cohort, only 50% (4/8) of heparinised and 50%
(2/4) of warfarinised patients achieved adequate
thromboprophylactic levels prior to the onset of CKD 5.
Bleeding events occurred in 1 of 4 warfarinised patients.
The only thrombosis on treatment developed with enoxaparin
at an adequate thromboprophylactic level. The small sample
size precludes formal analysis or recommending one agent
over another. All patients were initially heparinised, with war-
farin used as second-line thromboprophylaxis in our unit. It is
plausible that adequate thromboprophylaxis is more readily
achieved later in the disease course, due to patients being more
stable, or having reduced overall proteinuric loss. A larger
cohort of patients receiving either warfarin or enoxaparin ini-
tially would be required to truly determine the more effica-
cious agent. For reasons previously described, this is unlikely
to occur.
Patient 7 required a significantly lower dose of enoxaparin
to reach target anti-factor Xa levels. This could be partly ex-
plained by the patient’s early development of significant CKD
and lesser degree of proteinuria. This patient also represents
the only included patient with LAMB2 mutation, again indi-
cating genotypic variability.
All patients had CVCs. This is an established risk factor for
the development of VTEs; in one reported cohort ~ 5% of
paediatric patients with CVCs in situ had at least one VTE
[28]. In both cases of thrombus in this cohort (patient 6 and 8),
thrombus was detected within a catheterised or recently cath-
eterised vessel, and within 2 weeks of initial presentation. As a
CVC is often fundamental to CNS management, risk mitiga-
tion can only be via timely thromboprophylaxis. Using higher
than BNFc recommended initial dosing may achieve this,
though that conclusion cannot be drawn from our cohort [14].
Warfarin has many potential medication interactions which
could have prevented target INRs. All warfarinised patients
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altered warfarin’s pharmacodynamics. Additionally, patient 5
developed a central line sepsis and thrombocytopenia. This
could partly explain why this patient had repeated bleeding
events coinciding with supraphysiological INRs. Yet, in this
patient population there are likely to be many unavoidable
confounders to therapeutic warfarinisation due to the com-
plexities of CNS management.
Though multiple medications can potentiate or inhibit the
actions of thromboprophylaxis, the doses of concomitant
medications used routinely in these patients (e.g. antibiotic
prophylaxis) were typically standard and infrequently altered.
The effect on thromboprophylaxis pharmacokinetics would
therefore be consistent and unlikely to account for sudden
changes in INR or anti-factor Xa. These patients are complex
with multiple factors impacting on both pharmacokinetics and
pharmacodynamics—further supporting the need for regular
therapeutic surveillance.
The management of CNS typically includes regular infu-
sions of IV albumin, the dose of which reflects the degree of
proteinuria. Weekly albumin doses varied within the cohort
from 5 to 32 g/kg/week (Supplementary Table 2). There was
no apparent association between dose of albumin adminis-
t e r e d a n d l i k e l i h o o d o f a c h i e v i n g a d e q u a t e
thromboprophylaxis. Patient 4 in this cohort never required
IV albumin, and had a different clinical course, similar to that
seen in Maori populations. Yet this patient was the most dif-
ficult patient to manage thrombotic risk, failing both LMWH
and warfarin despite prolonged treatment with both [1].
Two patients had a long period of sub-therapeutic treat-
ment of enoxaparin with minimal dosing changes (Fig. 1:
patient 1: 25 weeks, patient 2: 27 weeks). Prolonged sub-
therapeutic therapy could increase the VTE risk, necessitating
consideration of conversion to warfarin. Achieving effective
thromboprophylaxis for these patients was challenging, as in
some eGFR increased with time, possibly resulting in elevated
clotting factor excretion. Clinical instability may cause clini-
cians to be reluctant to alter medication dosage, which may
partly explain the long sub-therapeutic period. Conversely,
one warfarinised patient was converted back to enoxaparin
due to safety concerns from unstable and excessive INR,
and two episodes of gastrointestinal bleeding.
The cohort is from a single national centre with 100%
patient identification over a 15-year period, with all patients
treated by the same clinical team thereby reducing variability
in clinical treatment.
This dataset is (to our knowledge) unique in showing the
relationship between anticoagulant dosing, therapeutic drug
levels, and kidney function in patients with CNS. The optimal
therapeutic regimen in this patient population has not been
ascertained. Though our cohort is too small to definitively com-
ment on dosing regimen or choice of thromboprophylaxis, the
safety profiles confirm the importance of measuring therapeutic
levels regularly in this complex patient group.
There are limitations to this cohort. The patient group were
heterogeneous, histologically and genetically, which may
have conferred different risk profiles of VTE [27]. The vari-
ability in clinical course affecting both proteinuria and kidney
function will also have an impact on interpretation. This het-
erogeneity further highlights the difficulties in establishing an
evidence base for thromboprophylaxis in CNS.
The small sample size precludes statistical analysis, un-
avoidable due to the disease rarity. A sufficiently large cohort
would mandate further international trials, but the most recent
effort demonstrated how challenging this is. Despite engaging
22 tertiary European centres, that study failed to recruit
enough patients to achieve statistical power for outcomes [22].
The limited data on proteinuria prevents interrogation of
the relationship between therapeutic drug levels and urinary
protein. Retrospective review of healthcare records for out-
come reporting is recognised to have flaws, as minor but clin-
ically relevant episodes may not be reported or poorly docu-
mented. This is somewhat mitigated by the lengthy in-patient
stays of these patients. All adverse events have occurred in a
hospital setting.
For three patients (4–6) length data was unavailable in the
early parts of life, so eGFR was calculated by retrospective
extrapolation using the patient’s nearest available length centile.
This may overestimate earlier length as early management of
CNS includes optimising nutrition and growth. To limit the
impact of this, the outcome of CKD 5 was only assigned when
using either a confirmed patient length, or where kidney re-
placement therapy was required. It is plausible that early kidney
function was overestimated for those patients.
Conclusions
This case series demonstrates that achieving adequate and
stable thromboprophylaxis in children with CNS is challeng-
ing. All bleeding events were associated with supra-
therapeutic levels. Development of thrombus prior to or short-
ly after any thromboprophylaxis highlights the importance of
commencing this early. Enoxaparin doses required for
thromboprophylaxis in this patient population were approxi-
mately double the recommended dose.
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